Billy Amzal - Frédéric Bois Bayesian Optimal Design for the Study of Butadiene Toxicokinetics
|
Celine Brochot, William Couet, Andrew Gelman, Frederic Yves Bois Assessing the Additivity of the Effects of Drugs in Mixtures
|
Mick Looby Assessing the robustness of competing dose regimens to incomplete compliance
|
Stefano Zamuner, Roberto Gomeni, Alan Bye Estimate the time varying brain receptor occupancy in PET imaging
|
Elena Mishina and Mehul Mehta Assessment of the Contribution of Components in a Combination Drug Product Using Population PK Modeling
|
R. H. Leary(1), R. Jelliffe(2), A. Schumitzky(2), and M. Van Guilder(2) A Unified Parametric/Nonparametric Approach to PK/PD Population Modeling
|
Bruce Green and Stephen Duffull Population pharmacokinetics and pharmacodynamics of enoxaparin in obese patients
|
Stephen Duffull and Bruce Green Prospective assessment of a D-optimal design for a population pharmacokinetic study of enoxaparin
|
Vladimir Piotrovsky Drug Efficacy Analysis as an Exercise in Dynamic (Indirect-Response) Population PK-PD Modeling
|
Nick Holford, Jianguo Li, Lisa Benincosa, Mattias Birath Population Disease Progress Models for the Time Course of HAMD Score in Depressed Patients Receiving Placebo in Anti-Depressant Clinical Trials
|
Marie Gårdmark Regulatory aspects of population pharmacokinetic drug interaction studies
|
Iñaki F. Trocóniz*, Ilonka Zsolt**, María J. Garrido*, Marta Valle**, and Manel J. Barbanoj** Dealing with Autoinhibition of Drug Clearance in Early Clinical Product Development
|
Freidig A, Onderwater R, Bogaards J, Bouzom F and Jochemsen R. Development of a PBPK model for drug-drug interaction of orally delivered drugs using in-vitro data
|
Jan Freijer, Bart Ploeger, Joost DeJongh & Meindert Danhof Extrapolation of pharmacokinetics and toxicity from pre-clinical data to humans
|
Sylvie Retout, France Mentré Optimisation Of Individual And Population Pharmacokinetic Designs Using S-Plus
|
Brigitte Tranchand1, Silvy Laporte2 Design and practical problems in population PK studies in the elderly
|
Lewis Sheiner, MD. Dealing With Missing Data Through Random Effects Models
|
Christian Laveille, PharmD (1), Lewis Sheiner, MD (2), Vincent Duval, PharmD (1), Guillemette Resplandy, PhD (1), and Roeline Jochemsen, PhD (1) Simulations using a mechanistic DDI model: individual risk assessment.
|
Charles Warlow Sub-group Nonsense. Problems In Interpreting And Considering Covariates In Evaluation
|
Jose Pinheiro Transformations and Variance Functions in Nonlinear Mixed-Effects Models
|
Eric Snoeck Model Evaluation
|
Oscar Della Pasqua(1) and Eliane Fuseau(2) Optimising Design In Paediatric Regulatory Studies
|